IO Frontiers World 2019


Kai Pinkernell

Dr Kai Pinkernell

Senior Vice President Medical Affairs, Chief Medical Officer, Medigene AG

Dr. Kai Pinkernell is Senior Vice President Medical Affairs, Chief Medical Officer, at Medigene AG and responsible for clinical and GMP process development. Medigene AG is a stock listed (Frankfurt: MDG1, Prime Standard) biotechnology company with its headquarters in Martinsried, Munich. Medigene concentrates on the development of personalized immunotherapies with a focus on hematooncology

Previously, Dr. Pinkernell was the Global Head of Clinical Business at Miltenyi Biotec GmbH, leading clinical marketing, sales and development, worldwide. Also, Dr. Pinkernell has been with Cytori Therapeutics Inc., San Diego, USA, from 2005 to 2009, as Senior Director of Regenerative Cell Technology and Clinical Applications Director. He received his medical degree from the Westfaelische-Wilhems University in Muenster, Germany, and pursued a residency/fellowship in internal medicine/cardiology at the German Heart Center and Klinikum Rechts der Isar, Technical University, in Munich, Germany. He further received a Master of Business Administration from the Marshall School of Business at the University of Southern California, Los Angeles, USA.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy